Dinutuximab: all 34 studies that test it
Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.Not yet recruitingNCT07853105Phase 1/2
- Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk NeuroblastomaRecruitingNCT07688252Phase 1
- Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and GanglioneuroblastomaRecruitingNCT07375563Phase 3
- A Multi-Arm, Platform Trial For Relapsed NeuroblastomaRecruitingNCT07334301Phase 1/2
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabNot yet recruitingNCT07261241Phase 2
- International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing SarkomaNot yet recruitingNCT06839703Phase 1
- Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue SarcomasRecruitingNCT06669013Phase 3
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialRecruitingNCT06450041Phase 2
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaRecruitingNCT06172296Phase 3
- Quadruple Immunotherapy for NeuroblastomaRecruitingNCT05754684Phase 2
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)RecruitingNCT04221035Phase 3
- High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)RecruitingNCT01704716Phase 3
- Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk NeuroblastomaCompletedNCT05373901Phase 1Results posted
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Active, not recruitingNCT04385277Phase 2Results posted
- A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including NeuroblastomaCompletedNCT04238819Phase 1/2Results posted
- Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedNCT03786783Phase 2Results posted
- Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung CancerCompletedNCT03098030Phase 2/3Results posted
- Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent OsteosarcomaCompletedNCT02484443Phase 2Results posted
- Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed NeuroblastomaCompletedNCT01767194Phase 2Results posted
- ch14.18 Pharmacokinetic Study in High-risk NeuroblastomaCompletedNCT01592045Phase 1/2Results posted
- Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedNCT01041638Phase 3Results posted
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedNCT00026312Phase 3Results posted
- Qarziba for Patients in Relapsed/Refractory High-grade OsteosarcomaSuspendedNCT05558280Phase 2
- Rapid Administration Pilot for Infusing DinutuximabActive, not recruitingNCT05421897Phase 2
- Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With LeiomyosarcomaCompletedNCT05080790Phase 2
- NK Cells Infusions With Irinotecan, Temozolomide, and DinutuximabActive, not recruitingNCT04211675Phase 1/2
- Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed NeuroblastomaStatus unknownNCT02743429Phase 2
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsActive, not recruitingNCT02573896Phase 1
- Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in ChildrenCompletedNCT02308527Phase 2
- CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed NeuroblastomaCompletedNCT02258815Phase 2
- Safety Study of Dinutuximab Combined With Immunotherapy to Treat NeuroblastomaCompletedNCT02169609Phase 2
- Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent NeuroblastomaActive, not recruitingNCT01711554Phase 1
- ch14.18/CHO Bridging StudyCompletedNCT01704872Phase 1
- Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With NeuroblastomaCompletedNCT00005576Phase 1